ERBB2 and acute myeloid leukemia: In addition to AML (21), myeloma (28), and melanoma (20) using the parental NK-92 cells, CAR-modified NK-92 have been shown to eliminate AML [CD33.CAR (29)], lymphoma [CD19.CAR (18)], myeloma [CS1.CAR (25)], prostate cancer [EpCAM.CAR (30)], breast cancer [Her-2.CAR (31)], neuroblastoma [GD2.CAR (32)], and glioblastoma [EGFR.CAR (33)].